AGTR1 and cancer: Based on RASi clinical data, three Phase II trial designs are proposed to validate the efficacy of polyphenols in cancer treatment: (1) The first trial targets metastatic CRC, building on the synergy between losartan and vitamin D. This trial would enroll 150 patients stratified by AT1R expression.